Andreas Hochhaus

Jena University Hospital — Germany

Medicine · Health Sciences

128h-index89.7kcitations1.6kworks5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Myeloid Leukemia Treatments(1119), Chronic Lymphocytic Leukemia Research(837), Eosinophilic Disorders and Syndromes(441), Acute Myeloid Leukemia Research(252), Acute Lymphoblastic Leukemia research(205)

Publications1.6k total

Randomized Comparison of Cardiotoxicity With 60 Versus 90 mg Daunorubicin in <scp>AML</scp> Induction Therapy
American Journal of Hematology·2026Open Access
Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing
Leukemia·2025Open Access
Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centered perspective
Leukemia·2025· 1 citedOpen Access
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial
Blood·2025· 2 citedOpen Access
Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few more
Leukemia·2025Open Access
40 years of LEUKEMIA
Leukemia·2025Open Access
Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes
Leukemia·2025Open Access
BCR::ABL1/GUSB halving times predict molecular response to asciminib at 18 months
Blood·2025Open Access
Evaluating reverse transcriptase efficiency in CML: Consequences for deep molecular response classification and treatment-free remission decisions
Blood·2025
Improved long-term tolerability with asciminib (ASC) vs investigator-selected (IS) tyrosine kinase inhibitors (TKIs) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Week 96 exploratory analysis of the phase 3 ASC4FIRST trial
Blood·2025
Vexas syndrome in Germany: Insights from a prospective registry on clinical presentation, management and outcomes
Blood·2025Open Access
A phase II Study of fedratinib and nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment – fraction Study / IKF051 / gsg-MPN-006
Blood·2025Open Access
CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML
Blood·2025· 2 cited
Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts
Blood·2025· 1 cited
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”
Blood·2025Open Access
Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform
Blood·2025Open Access
Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis
Blood·2025Open Access
Nanopore sequencing to detect BCR::ABL1 and associated genomic rearrangements in CML
Blood·2025Open Access
Improved long-term tolerability and efficacy of asciminib-based combination therapies in newly diagnosed CML patients - the fascination trial.
Blood·2025Open Access
Single versus double “7+3” induction with 60 versus 90 mg/m2 daunorubicin in newly diagnosed AML: Does it matter for NPM1 MRD?
Blood·2025
page 1 of 82Next →

Frequent Co-authors

Timothy P. Hughes(22), Hagop M. Kantarjian(19), Michele Baccarani(18), François Guilhot(16), Richard A. Larson(16), Giuseppe Saglio(16), Jörge E. Cortes(13), Jerald P. Radich(12), John M. Goldman(10), Brian Druker(10), Michael W. Deininger(10), Dong‐Wook Kim(10), Jane F. Apperley(9), Francisco Cervantes(9), Susan Branford(8), Martin C. Müller(8), Neil P. Shah(7), Delphine Réa(7), Nicholas C.P. Cross(6), Stephen G. O’Brien(6)